Current Report Filing (8-k)
February 25 2020 - 7:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8–K
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
February 25, 2020
ZYNERBA
PHARMACEUTICALS, INC.
(Exact Name of Issuer as Specified in Charter)
Delaware
|
|
001-37526
|
|
26-0389433
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
(Address of Principal Executive Offices)
(484) 581-7505
(Registrant’s Telephone Number, Including
Area Code)
Not Applicable
(Former Name or Former Address, if Changed
Since Last Report)
Securities registered pursuant to Section
12(b) of the Act:
Check the appropriate box below if the Form 8–K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)
|
¨
|
Pre–commencement
communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))
|
¨
|
Pre–commencement
communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))
|
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
|
ZYNE
|
|
The NASDAQ Global Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 8.01 Other
Events
On February 25, 2020, Zynerba Pharmaceuticals,
Inc. (the “Company”) issued a press release announcing that the U.S. Patent and Trademark Office issued U.S.
Patent No. 10,568,848, titled “Treatment of Autism with Cannabidiol” which includes claims directed to methods of treating
autism spectrum disorder (ASD) by transdermally administering, via a gel or cream, a therapeutically effective amount of purified
cannabidiol (CBD). A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial
Statements and Exhibits
The following exhibits are being filed herewith:
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 25, 2020
|
ZYNERBA PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/
Suzanne Hanlon
|
|
|
Name: Suzanne Hanlon
|
|
|
Title: Secretary, Vice President and General
Counsel
|
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Sep 2023 to Sep 2024